Current status of cytotoxic chemotherapy in patients with metastatic prostate cancer.
Despite efforts at early detection with prostate specific antigen-based screening, more than 25,000 patients in the United States will die this year of metastatic prostate cancer. As a consequence both of screening and increased use of androgen deprivation therapy, patients commonly present with low volume, asymptomatic, metastatic disease. Over the past 2 decades chemotherapy for advanced prostate cancer has evolved from a frightful, toxic experience to one that frequently provides clinically meaningful palliation and a modest, but real survival benefit. With the establishment of docetaxel-based chemotherapy as initial therapy, efforts are underway to evaluate the role of second-line systemic therapy options.
Dreicer
Robert
R
Department of Solid Tumor Oncology and the Taussig Cancer and Glickman Urologic and Nephrology Institutes, Cleveland Clinic, Cleveland, OH 44195, USA. Dreicer@ccf.org
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077143:Docetaxel; D006801:Humans; D008297:Male; D008942:Mitoxantrone / Q000627:therapeutic use; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D043823:Taxoids / Q000627:therapeutic use
D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D008942:Mitoxantrone